Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 19/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325414 | 1.00 | EPHX2 (0.59) | EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL3323667 | 1.00 | EPHX2 (0.59) | EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL3325008 | 0.98 | EPHX2 (0.59) | EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL3321987 | 0.98 | EPHX2 (0.59) | EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL3321991 | 0.98 | EPHX2 (0.59) | EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL3326481 | 0.85 | ALDH1A1 (0.53) | — | |
| SCHEMBL3324551 | 0.85 | EPHX2 (0.57) | EPHX2 | |
| SCHEMBL3324547 | 0.85 | EPHX2 (0.57) | EPHX2 | |
| SCHEMBL2403542 | 0.85 | DPP4 (0.58) | EPHX2 | |
| SCHEMBL2403540 | 0.85 | DPP4 (0.58) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| CN-101374825-A | Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1976840-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2007080140-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES AND THEIR USE AS HISTAMINE H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | EPHX2 3709/4885EPHX1 2498/4885CYP2C9 1107/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | EPHX2 3709/4885EPHX1 2498/4885CYP2C9 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.